FOLH1 and prostate carcinoma: Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein predominantly expressed in prostatic tissue, with expression levels significantly increased in prostate cancer cells [74], particularly in high-grade, metastatic, and hormone-refractory tumours [75].